Correction to my earlier post: the best group by far was the group with the intermediate doseage, the brown line on the graph.
Before jumping to conclusions, a possibility exists that one or two patients responded far better than the others to generate this result. It might also have been the case with the phase 1 patients that one of them did much better than the others. So it could be that response has been more influenced by the patient disease characteristics more than the dose given.
Which is why I said earlier that patient selection is often the reason for trial failure.
Anyway, they will have the 52 week data for the first cohort already, and for the second cohort just before Christmas. That may provide some further insight. Presumably since they didn't mention the 52 week data they have, it didn't reveal anything new.
- Forums
- ASX - By Stock
- 1AI
- Ann: Results of LCT Parkinsons trial require further analysis
Ann: Results of LCT Parkinsons trial require further analysis, page-31
-
- There are more pages in this discussion • 133 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add 1AI (ASX) to my watchlist
|
|||||
Last
0.9¢ |
Change
-0.001(10.0%) |
Mkt cap ! $15.18M |
Open | High | Low | Value | Volume |
0.9¢ | 0.9¢ | 0.9¢ | $750 | 83.33K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 206531 | 0.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.0¢ | 383746 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 206531 | 0.009 |
11 | 5386180 | 0.008 |
8 | 6360009 | 0.007 |
6 | 2493750 | 0.006 |
4 | 2300000 | 0.005 |
Price($) | Vol. | No. |
---|---|---|
0.010 | 383746 | 1 |
0.011 | 1277832 | 10 |
0.012 | 2385405 | 7 |
0.013 | 894768 | 4 |
0.014 | 126665 | 2 |
Last trade - 14.28pm 12/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
TLX
Telix jumps 11.6% as US government indicates proposed medicare changes won't affect prostate cancer drug
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
1AI (ASX) Chart |